国际多中心验证新辅助治疗后18F-FDG PET/CT最大标准化摄取值4.0阈值指导胰腺导管腺癌手术选择
这项国际多中心回顾性研究分析了923例接受新辅助治疗后可切除或交界可切除胰腺导管腺癌患者,基于2017-2019年 derivation 队列(n=413)得出新辅助治疗后最大标准化摄取值(SUVmax)4.0阈值,并在2020-2021年独立验证队列(n=510)中验证。结果显示SUVmax≥4.0与较差总生存独立相关,联合CA19-9可分层无复发生存和总生存,高SUVmax与远处失败相关而非切缘失败。
要点
- 新辅助治疗后SUVmax≥4.0是独立不良预后因素,验证队列HR 1.53。
- SUVmax联合CA19-9可清晰分层无复发生存和总生存。
- 双阳性(SUVmax≥4.0且CA19-9>37 U/mL)6个月内早期复发率32%。
核心结论
- 新辅助治疗后SUVmax阈值4.0是可重复的单时间点代谢标准,补充CA19-9实现生物学指导的手术选择。
研究设计与样本
- 国际多中心回顾性研究,纳入923例接受新辅助治疗、术前FDG PET/CT及胰腺切除术的可切除或交界可切除胰腺导管腺癌患者。
- 2017-2019年 derivation 队列413例得出SUVmax阈值4.0,2020-2021年独立验证队列510例不重新优化验证。
主要发现
- SUVmax≥4.0与较差总生存独立相关:derivation队列HR 1.86(95%CI 1.40-2.45),验证队列HR 1.53(95%CI 1.13-2.07)。
- SUVmax(≥4.0 vs <4.0)联合新辅助治疗后CA19-9(>37 vs ≤37 U/mL)对无复发生存和总生存产生清晰阶梯式分离。
- SUVmax≥4.0对6个月内早期复发预测能力中等(AUC 0.65)。
- 双阳性规则(SUVmax≥4.0且CA19-9>37 U/mL)特异性0.83、敏感性0.42,该亚组6个月内早期复发率32%。
- 高SUVmax与远处失败相关,而非切缘相关失败。
关键数值与推荐
- 新辅助治疗后SUVmax≥4.0为预后不良阈值。
- 新辅助治疗后CA19-9>37 U/mL为联合分层阈值。
- 双阳性定义为SUVmax≥4.0且CA19-9>37 U/mL。
临床怎么用
- 对于解剖学可切除或交界可切除胰腺导管腺癌,新辅助治疗后可行FDG PET/CT测量SUVmax,以4.0为界辅助识别生物学高危患者。
- 结合CA19-9水平(>37 U/mL)可进一步分层,双阳性患者6个月内早期复发风险较高,可考虑更谨慎的手术决策或强化围术期管理。
局限性
- 回顾性研究设计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine whether a single post-neoadjuvant therapy fluorodeoxyglucose positron emission tomography combined with computed tomography measurement and maximum standardized uptake value can guide surgical selection in anatomically resectable or borderline-resectable pancreatic ductal adenocarcinoma. Limitations of morphologic computed tomography because of neoadjuvant therapy-induced changes require decision-time biomarkers reflecting residual tumor biology. METHODS: This international multicenter retrospective study analyzed 923 patients with resectable or borderline-resectable pancreatic ductal adenocarcinoma who underwent neoadjuvant therapy, preoperative fluorodeoxyglucose positron emission tomography combined with computed tomography, and pancreatectomy. An outcome-based post-neoadjuvant therapy maximum standardized uptake value threshold of 4.0 was derived from a temporal derivation cohort (2017-2019; n = 413) and validated without reoptimization in an independent cohort (2020-2021; n = 510). The end points were overall survival, recurrence-free survival, early recurrence within 6 months, and first-failure pattern. RESULTS: Post-neoadjuvant therapy maximum standardized uptake value ≥4.0 was independently associated with inferior overall survival (derivation: hazard ratio, 1.86; 95% confidence interval, 1.40-2.45; validation: hazard ratio, 1.53; 95% confidence interval, 1.13-2.07). Combining maximum standardized uptake value (≥4.0 vs <4.0) with post-neoadjuvant therapy carbohydrate antigen 19-9 (>37 vs ≤37 U/mL) yielded clear stepwise separation of recurrence-free survival and overall survival. Maximum standardized uptake value ≥4.0 modestly predicted early recurrence within 6 months (area under the curve, 0.65), whereas a "double-positive" rule (maximum standardized uptake value ≥4.0 and carbohydrate antigen 19-9 >37 U/mL) increased specificity (0.83) with lower sensitivity (0.42), with 32% early recurrence within 6 months in this subgroup. A high maximum standardized uptake value was associated with distant but not margin-related failure. CONCLUSION: A post-neoadjuvant therapy maximum standardized uptake value threshold of 4.0 defined a reproducible, single-time-point metabolic criterion that complemented carbohydrate antigen 19-9 level to enable biology-guided surgical selection in anatomically resectable pancreatic ductal adenocarcinoma.
引用
- Ikenaga N, Kim HS, Baba S, et al. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 threshold to guide surgical selection in pancreatic ductal adenocarcinoma following neoadjuvant therapy. Surgery. 2026. PMID: 42957525. doi:10.1016/j.surg.2026.110503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。